Mitobridge

An Astellas Company

targeting mitochondria advancing human health

down down
Discovering and developing therapeutics that enhance mitochondrial functions
Employing an integrated platform to evaluate mitochondrial activity
Building upon the evolving data linking mitochondrial dysfunction to disease
prevnext

About Mitobridge

Mitobridge is discovering and developing novel therapeutics that improve mitochondrial functions. Building upon the emerging scientific findings linking mitochondrial dysfunction with disease pathologies, we are progressing innovative approaches to the treatment of diseases with high unmet medical need. Our strategy is to establish proof of concept in rare diseases and then expand into more common diseases. Mitobridge has assembled a strong team with expertise in advancing ground-breaking therapeutics into the clinic. Our scientific founders and advisors include leaders in mitochondrial biology, metabolism and aging with experience in translating novel discoveries into next-generation medicines. We are also using this biology based approach to explore other important pathways with high potential for clinical impact.

Mitobridge Inc. was founded in 2013 with financing from MPM Capital, Longwood Fund, and Astellas Pharma’s Venture Management team, all sharing a vision for the promise of mitochondrial-targeted therapeutics. In January of 2018, Mitobridge was acquired by Astellas Pharma and is now Mitobridge, an Astellas Company. At Astellas, mitochondrial biology is one of our Primary Focuses, and this biology platform drives our commitment to bring new biological concepts into the clinic for rapid proof of concept.

up